It is now well established that the vascular endothelium serves as far more than a simple physical barrier between blood and interstitial fluid. Deemed to play a central role in the regulation of the vascular tone and permeability, it is furthermore involved in pathological conditions such as diabetic retinopathy and psoriasis as well as tumor growth (1, 2) . Angiogenesis, the sprouting of new capillaries from preexisting blood vessels, has been found to be a crucial component in the pathogenesis of these disorders (1) . During the angiogenesis process, endothelial cells (EC) 1 are stimulated to migrate, proliferate, and invade surrounding tissue to form capillary tubules capable of carrying blood, resulting in part from the action of soluble EC-directed growth factors (1) . By virtue of its multifunctional nature, vascular endothelial growth factor (VEGF) is a likely candidate for the regulation of both physiological and pathophysiological angiogenesis (3) . Initially identified in the media conditioned by tumor cell lines as vascular permeability factor (4), VEGF is also synthesized and released from normal cells such as vascular smooth muscle cells, lung epithelium, and pituitary folliculo-stellate cells (5, 6) . According to ligand autoradiography studies, the systemic effects of VEGF are thought to be mostly restricted to EC, since high affinity VEGF-binding sites were found to be almost exclusively localized to the vascular endothelium of large and small vessels (7, 8) .
Although VEGF and other growth factors including acidic and basic fibroblast growth factors and epidermal growth factor are able to stimulate EC growth and migration in vitro and angiogenesis in vivo (9) , only VEGF is capable of enhancing protein vascular permeability (10) . We have recently reported that VEGF-induced protein extravasation in vivo could be abolished by pretreatment with a selective platelet-activating factor (PAF) receptor antagonist (11) . In addition, we showed that VEGF promoted a dose-dependent increase of PAF synthesis by cultured bovine aortic endothelial cells (BAEC), suggesting that VEGF enhances vascular permeability through PAF synthesis (11) .
VEGF exerts its multiple actions by binding to tyrosine kinase receptors, namely the fms-like tyrosine kinase Flt-1 and the fetal liver kinase receptor Flk-1 (KDR) (12) (13) (14) (15) . Many studies have shown that these two receptors may play a leading role in VEGF-induced angiogenesis. For instance, stimulation of either receptor by VEGF triggers its phosphorylation, followed by an intracellular calcium elevation (16) . In addition, their expression was shown to be up-regulated in some metastasic tumors (17) , in regenerating liver following injury (18) , in infarcted heart (19) , and in diabetic retina (20) . Recent investigations suggest that the single activation of Flk-1 alone is sufficient to induce most VEGF effects (16, (21) (22) (23) . However, since the murine knockout of either Flt-1 or Flk-1 is lethal (24, 25) and since VEGF receptors can possibly form heterodimers (16) , it remains unclear if the contribution or the presence of both receptors is required independently or simultaneously in numerous VEGF-related events. The role of the two receptors in PAF synthesis mediated by VEGF is also unknown. To distinguish the contribution of Flt-1 and Flk-1 receptors upon EC stimulation by VEGF, we used selective antisense deoxyribophosphorothioate oligomers that hybridized specifically with a complementary mRNA sequence and prevented the translation of the targeted mRNA into its protein (26 -28) . Hence, this antisense gene expression knockdown approach enabled us to down-regulate the protein expression of Flt-1 or Flk-1 in a highly selective fashion and thus to evaluate their contribution to the biological activities mediated by VEGF.
In the present study, we examined the mitogenic, chemotactic, and PAF synthesis activities of VEGF on BAEC. We then investigated the potency of antisense oligonucleotide sequences complementary to Flt-1 or Flk-1 mRNA in modulating VEGF effects. We report here that the activation of Flk-1 is sufficient to mediate fully the VEGF actions on EC in vitro and that the presence of Flt-1 is not required. This point is strengthened by the use of placenta growth factor (PlGF), an Flt-1-specific agonist (22) , which failed to elicit BAEC proliferation and migration and had only a very minor effect on PAF synthesis. These data bring new insights to our understanding of the mechanisms by which VEGF mediates its effects on endothelial cells.
MATERIALS AND METHODS
Cell Culture-BAEC expressing both VEGF receptors (36) were isolated from freshly harvested aorta, cultured in Dulbecco's modified eagle medium (DMEM; Life Technologies, Inc.) containing 5% fetal bovine serum (Hyclone Laboratories, Logan UT), and antibiotics (Sigma). BAEC were characterized by their cobblestone monolayer morphology and factor VIII immunohistochemistry and were not passaged for more than nine cycles.
Antisense Oligonucleotide Therapy-To distinguish the contribution of Flt-1 and Flk-1 upon stimulation of EC by VEGF, we treated BAEC with antisense oligonucleotide sequences complementary to bovine Flt-1 or Flk-1 mRNA (GenBank accession numbers X94263 and 94298). A total of four different antisense oligonucleotide phosphorothioate backbone sequences were used, two targeting bovine Flt-1 mRNA (antisense 1, AS1-Flt: 5Ј-CAA AGA TGG ACT CGG GAG-3Ј; antisense 2, AS2-Flt: 5Ј-GTC GCT CTT GGT GCT ATA-3Ј), and two targeting bovine Flk-1 mRNA (antisense 1, AS1-Flk: 5Ј-GCT GCT CTG ATT GTT GGG-3Ј; antisense 2, AS2-Flk: 5Ј-CCT CCA CTC TTT TCT CAG-3Ј). Two scrambled phosphorothioate sequences (scrambled Flt, SCR-Flt: 5Ј-AGC TAG GCA CGA GAG TGA-3Ј; scrambled Flk, SCR-Flk: 5Ј-TGC TGG CAT GTG CGT TGT-3Ј) were also used as negative controls. These sequences were designed with no more than three consecutive guanosines and by minimizing their capacity to form hairpins and dimers. All sequences were synthesized at the Armand Frappier Institute (Laval, Canada). After synthesis, the oligonucleotides were dried, resuspended in sterile water, and quantified by spectrophotometry. The assurance that the antisense oligomer solutions were by-product-free was confirmed by denaturing polyacrylamide gel electrophoresis (20%; 7 M urea), based on the known length of the oligonucleotide.
Western Blot Analysis of Flt-1 and Flk-1 Protein Expression-The efficiency and specificity of our antisense sequences to block the targeted protein expression were evaluated by Western blot analysis. Confluent BAEC (100-mm tissue culture plate) were washed with DMEM and trypsinized (trypsin-EDTA; Life Technologies). Cells were resuspended in DMEM containing 5% of fetal bovine serum and antibiotics, and a cell count was obtained with a Coulter counter Z1 (Coulter Electronics, Luton, UK). Cells were seeded at 1 ϫ 10 6 cells/100-mm tissue culture plate (Becton-Dickinson, Rutherford, NJ), stimulated for 24 h in DMEM, 5% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M) and starved for 48 h in DMEM, 0.25% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M daily) for G 0 synchronization. The cells were then grown to confluence for 16 h in DMEM, 1% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M) and starved for 8 h in DMEM, 0.25% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M) to induce an up-regulation of the VEGF receptors expression. Culture medium was removed, and cells were rinsed twice with ice-cold DMEM. Total proteins were prepared by the addition of 500 l of lysis buffer containing phenylmethylsulfonyl fluoride 1 mM (Sigma), leupeptin 10 g/ml (Sigma), aprotinin 30 g/ml (Sigma), and NaVO 3 1 mM (Sigma). Plates were incubated at 4°C for 30 min and scraped, and the protein concentration was determined with a Bio-Rad protein assay kit. Immunoprecipitation was performed on 12 mg of total proteins for each sample by incubation with rabbit anti-mouse Flk-1 IgG or rabbit anti-human Flt-1 IgG polyclonal antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) bound to protein A-Sepharose beads at 4°C for 1 h. Both antibodies were specific for their targeted protein and do not cross-react with each other. After washing three times with lysis buffer, the immunoprecipitates were dissolved in Laemmli's buffer, boiled for 5 min in reducing conditions, separated by a 10 -20% gradient SDS-PAGE (Protean II kit; Bio-Rad), and transblotted onto a 0.45-m polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA). The membranes were blocked in 5% Blotto-TTBS (5% nonfat dry milk (Bio-Rad), 0.05% Tween 20, 0.15 M NaCl, 25 mM Tris-HCl, pH 7.5) for 2 h at room temperature with gentle agitation and incubated for 45 min in 1% Blotto-TTBS containing the desired antisera (anti-Flt-1 or anti-Flk-1; 1:100 dilution). Membranes were washed three times with TTBS, reblocked for 10 min in 1% Blotto-TTBS, and incubated with a horseradish peroxidase goat anti-rabbit IgG antibody (1:7500 dilution, Santa Cruz Biotechnology) in 5% Blotto-TTBS for 30 min. Membranes were washed with TTBS, and horseradish peroxidase bound to secondary antibody was revealed by chemiluminescence (Renaissance kit, NEN Life Science Products). Kaleidoscope molecular weight and SDS-polyacrylamide gel electrophoresis broad range marker proteins (Bio-Rad) were used as standards for SDS-polyacrylamide gel electrophoresis. Digital image densitometry (PDI Bioscience) was performed on x-ray films to determine relative percentages of Flt-1 or Flk-1 protein expression.
Western Blot Analysis of Flt-1 and Flk-1 Protein Phosphorylation-BAEC were pretreated with the antisense sequences as described above for Western blot analysis. Cells were then rinsed with DMEM, incubated on ice in DMEM plus 1 mg/ml bovine serum albumin plus VEGF (10 Ϫ9 M) for 30 min, incubated at 37°C for 7 min, and then brought back on ice. Cells were rinsed with DMEM plus NaVO 3 (1 mM), and total proteins were prepared as described. Immunoprecipitation was performed on 500 g of total proteins with rabbit anti-mouse Flk-1 IgG or rabbit anti-human Flt-1 IgG polyclonal antibodies (Santa Cruz Biotechnology) bound to protein G-Sepharose 4 Fast Flow (Amersham Pharmacia Biotech) at 4°C for 1 h. After three washes with lysis buffer, the immunoprecipitates were dissolved in Laemmli buffer, boiled for 5 min in reducing conditions, separated by a 6% SDS-polyacrylamide gel electrophoresis (Mini-Protean II kit; Bio-Rad), and transblotted onto a 0.45-m polyvinylidene difluoride membrane. The membranes were blocked in 3% bovine serum albumin-PBST (Tween 0.1%) for 1 h at room temperature and incubated overnight with the primary antisera (mouse anti-phosphotyrosine clone 4G10; 1:3000 dilution; Upstate Biotechnology, Inc., Lake Placid, NY). Membranes were washed with PBST, incubated with an anti-mouse IgG (1:4000 dilution; Santa Cruz Biotechnology), and washed with PBST, and chemiluminescence protocol was followed as described above.
Mitogenic Assays-Confluent BAEC were washed with DMEM and trypsinized. Cells were resuspended in 9 ml of DMEM, 5% FBS, and antibiotics, and a cell count was obtained. BAEC were seeded at 1 ϫ Chemotaxis Assays-Cell migration was evaluated using a modified Boyden 48-well microchamber kit (NeuroProbe, Cabin John, MD). Near confluent BAEC (100-mm tissue culture plate) were washed with DMEM and trypsinized. Cells were resuspended in DMEM, 5% FBS, and antibiotics, and a cell count was obtained. BAEC were seeded at 2.5 ϫ 10 5 cells/well of six-well tissue culture plates; stimulated for 24 h in DMEM, 5% FBS, and antibiotics with or without antisense oligomers (10 Ϫ7 M); and starved for 48 h in DMEM, 0.25% FBS, and antibiotics with or without antisense oligomers (10 Ϫ7 M daily). Cells were harvested by trypsinization and resuspended in DMEM, 1% FBS, and antibiotics at a concentration of 1 ϫ 10 6 cells/ml. 50 l of this solution with or without antisense oligomers (10 Ϫ7 M) was added in the higher chamber of the modified Boyden chamber apparatus, and the lower chamber was filled with DMEM, 1% FBS, and antibiotics plus the proper concentration of agonist (VEGF or PlGF). The two sections of the system were separated by a porous polycarbonate filter (5-m pores), pretreated with a gelatin solution (1.5 mg/ml), and assembled. Five hours postincubation at 37°C, the nonmigrated cells were scraped with a plastic policeman, and the migrated cells were stained using QuickDiff solutions. The filter was then mounted on a glass slide, and migrated cells were counted using a microscope adapted to a video camera to obtain a computer-digitized image.
Measurement of PAF Synthesis-PAF production by BAEC was measured by incorporation of [ 3 H]acetate into lyso-PAF (11). Confluent BAEC (100-mm tissue culture plate) were washed with DMEM and trypsinized. Cells were resuspended in DMEM, 5% FBS, and antibiotics, and a cell count was obtained. Cells were seeded at 5 ϫ 10 5 cells/well of six-well tissue culture plates; stimulated for 24 h in DMEM, 5% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M); and starved for 48 h in DMEM, 0.25% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M daily) for G 0 synchronization. The cells were then grown to confluence for 24 h in DMEM, 1% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M) and starved for 8 h in DMEM, 0.25% FBS, and antibiotics with or without antisense oligomers (1-5 ϫ 10 Ϫ7 M) to induce an up-regulation of VEGF receptor expression. Culture medium was removed, and cells were rinsed twice with Hank's balanced salt solution/HEPES (10 mM; pH 7.4). Cells were then stimulated for 15 min in 1 ml of Hank's balanced salt solution/HEPES (10 mM, pH 7.4) plus CaCl 2 (10 mM) plus [
3 H]acetate (25 Ci) plus the appropriate concentration of agonist (VEGF or PlGF). The reaction was stopped by the addition of acidified methanol (50 mM acetic acid), and the wells were scraped and added to chloroform (2.5 ml) and 0.1 M sodium acetate (1 ml) mixture. Culture plates were washed twice with 1 ml of methanol, added to the chloroform mixture, and centrifuged for 2 min at 1700 rpm. The upper phase was discarded, and the chloroform phase was washed twice with 2 ml of the organic phase of a Hank's balanced salt solution/HEPES (10 mM)/methanol/ chloroform/sodium acetate (0.1 M) solution (1:2.5:3.75:1). Isolated lipids were evaporated under a stream of N 2 gas, resuspended in 175 l of mobile phase solvent (water/chloroform/methanol, 5:40:55), and purified by HPLC. Samples were injected into a silica-based normal phase HPLC column (4.5 ϫ 250 mm, 5-m silica particle size; Varian, Harbor City, CA) and eluted with the mobile phase solvent at a 0.5 ml/min flow rate. Fractions were collected every min, and the amount of [ 3 H]PAF synthesized was quantified by counting radioactivity with a ␤-counter. 
RESULTS

Modulation of Flt-1 or Flk-1 Protein Expression by Antisense
Oligonucleotides-In order to determine the potency of antisense oligonucleotides to inhibit the targeted protein expression, BAEC were pretreated with either the antisense or the scrambled oligonucleotide sequences. Total proteins were extracted, quantified by bioassay, and immunoprecipitated with an anti-Flt-1 or an anti-Flk-1 antibody, and the expression of each receptor was determined by Western blot analysis. Digital image densitometry was performed, and results were expressed as relative expression percentages when compared with control PBS-treated cells. The basal protein expression of Flt-1 (Ctrl) was inhibited when the BAEC were pretreated with the two antisense oligomers complementary to Flt-1 mRNA (10 Ϫ7 M); the first antisense sequence (AS1-Flt) suppressed Flt-1 protein expression by 91%, while the second antisense sequence (AS2-Flt) showed a 94% inhibition effect (Fig. 1A) . Similar treatment with the two antisense sequences (AS1-Flk and AS2-Flk; 10 Ϫ7 M) complementary to Flk-1 mRNA suppressed basal Flk-1 protein expression by 80 and 78%, respectively (Fig. 1B) . Two scrambled sequences (SCR-Flt and SCRFlk; 10 Ϫ7 M) had no inhibitory effect on the studied receptor expression as compared with control cells (Fig. 1, A and B) . To achieve a greater inhibition of Flk-1 protein expression, BAEC were pretreated with a higher concentration of antisense oligomers (AS1-Flk and AS2-Flk; 5 ϫ 10 Ϫ7 M), resulting in a 99 and 94% suppression of Flk-1 protein expression, respectively (Fig. 1C) . The scrambled sequence (5 ϫ 10 Ϫ7 M) showed a slight reduction by 16% of Flk-1 protein expression (Fig. 1C) .
To ensure that the antisense oligomers designed to downregulate the expression of Flk-1 would not affect Flt-1 receptor expression and vice versa, we performed a Western blot analysis to evaluate the specificity of our most potent antisense oligomers. A pretreatment with our most potent antisense oligomer for the down-regulation of Flk-1 expression (AS1-Flk; 5 ϫ 10 Ϫ7 M) did not significantly affect Flt-1 basal expression ( Fig. 2A) , while our most potent antisense oligomer designed for the blockade of Flt-1 receptor expression (AS2-Flt; 5 ϫ 10 Ϫ7 M) almost completely blocked Flt-1 receptor expression ( Fig.  2A) . A pretreatment with AS1-Flk (5 ϫ 10 Ϫ7 M) severely impaired Flk-1 protein expression as compared with nontreated cells, while AS2-Flt (5 ϫ 10 Ϫ7 M) was without significant effect (Fig. 2B) .
Inhibition of VEGF-induced Flt-1 or Flk-1 Phosphorylation by Antisense Oligomers-Since the antisense sequences described herein were specific at blocking the targeted receptor expression, we sought to determine their potency to modulate Flt-1 and Flk-1 protein phosphorylation upon stimulation with VEGF. First, the stimulation of BAEC with VEGF (10
induced an increase of Flt-1 and Flk-1 phosphorylation by up to 1.5-and 13.2-fold, respectively, over PBS-treated cells (Fig. 3, A  and B) . Pretreatment with our most potent antisense oligomer directed against Flt-1 mRNA (AS2-Flt; 5 ϫ 10 Ϫ7 M) reduced by 50% the VEGF-induced phosphorylation of Flt-1 protein, while our most potent antisense oligomer directed against Flk-1 mRNA increased its phosphorylation by 13% (Fig. 3A) . A similar pretreatment with the AS1-Flk (5 ϫ 10 Ϫ7 M) inhibited by as much as 87% the phosphorylation of Flk-1 receptor (Fig. 3B) , while a pretreatment with AS2-Flt (5 ϫ 10 Ϫ7 M) slightly decreased Flk-1 phosphorylation in response to VEGF (10 Ϫ9 M) by 18% (Fig. 3B) .
VEGF and PlGF Mitogenic Activity on BAEC-We examined VEGF and PlGF mitogenic effects to distinguish the involvement of the two VEGF receptors on BAEC proliferation. Stimulation of quiescent BAEC with DMEM, 1% FBS raised the cell count from 10,080 Ϯ 520 to 19,180 Ϯ 600 cells within 72 h. The addition of VEGF (10 Ϫ11 , 10 Ϫ10 , and 2.5 ϫ 10 Ϫ10 M) increased endothelial cell proliferation dose-dependently with maximal induction of 62, 183, and 219%, respectively, as compared with DMEM, 1% FBS (Fig. 4) . In contrast, PlGF (10 Ϫ10 , 2.5 ϫ 10 Ϫ10 ,
10
Ϫ9
, and 10 Ϫ8 M) did not show any mitogenic activity on BAEC as compared with DMEM, 1% FBS (Fig. 4) . (Fig. 5) . Treatment of BAEC with the two antisense sequences directed against the Flk-1 mRNA completely blocked VEGF's mitogenic activity, while the antisense sequences directed against Flt-1 mRNA were without significant effect. The scrambled oligonucleotide sequences also failed to block VEGF-induced proliferation of BAEC.
VEGF and PlGF Chemotactic Activity on BAEC-Using a modified Boyden chamber assay, we studied the chemotactic response of BAEC to VEGF and PlGF. VEGF (10 Ϫ10 , 2.5 ϫ 10
Ϫ10
, and 10 Ϫ9 M) induced a dose-dependent increase (46, 83, and 130%, respectively) of BAEC migration as compared with PBS-stimulated cells, raising the migrated cell count from 120 Ϯ 4 (PBS) to 276 Ϯ 8 cells/mm 2 (10 Ϫ9 M VEGF; p Ͻ 0.001) 5 h post-treatment (Fig. 6 ). Checkerboard analysis revealed that the response of BAEC to VEGF was a result of chemotaxis and not chemokinesis (data not shown). Treatment with PlGF (10 Ϫ10 , 10
Ϫ9
, and 10 Ϫ8 M) had no significant effect on the basal migration of BAEC as compared with PBS-stimulated cells (Fig. 6) . did not significantly affect basal migration in the absence of VEGF. In contrast, the antisense oligonucleotide sequences complementary to Flk-1 mRNA, AS1-Flk, and AS2-Flk (10 Ϫ7 M), decreased by 91 and 80%, respectively, the migration elicited by VEGF. The use of the antisense sequences to Flt-1 mRNA (10 Ϫ7 M) did not alter VEGF-induced chemoattraction of BAEC. The scrambled oligonucleotide sequences did not significantly affect the chemotactic properties of VEGF (Fig. 7) .
Effects of Flk-1 and Flt-1 mRNA Antisense Oligonucleotides on VEGF Chemotactic Activity-Nonstimulated
VEGF and PlGF Effects on Endothelial Cell PAF Synthesis-To determine whether VEGF and PlGF stimulated PAF synthesis in EC, confluent BAEC were incubated with growth factors, and PAF synthesis was determined by metabolic incorporation of [ 3 H]acetate into lyso-PAF, the precursor of PAF synthesis. VEGF (10 Ϫ10 , 10 Ϫ9 , and 10 Ϫ8 M) dose-dependently elicited the synthesis of PAF, with increases of 7.2-, 20.4-, and 35.9-fold, respectively, as compared with PBS-treated cells (Fig. 8) . Treatment with PlGF (10 Ϫ10 , 10 Ϫ9 M) did not significantly affect the basal PAF synthesis of BAEC. However, at 10 Ϫ8 M, PlGF induced a slight but significant increase in PAF synthesis (67%) as compared with PBS-treated cells (Fig. 8) .
Effects of Flk-1 and Flt-1 mRNA Antisense Oligonucleotides on VEGF-induced PAF Synthesis-To determine the basal and maximal PAF synthesis by BAEC, a group of cells were left untreated, and others were treated with VEGF (10 Ϫ9 M) for 15 min. The synthesis of 3 H-labeled PAF increased from 781 Ϯ 86 to 8254 Ϯ 292 dpm (Fig. 9) . Treatment of BAEC with the antisense oligonucleotide sequences complementary to Flk-1 mRNA, AS1-Flk and AS2-Flk (10 Ϫ7 M), reduced by 77 and 75%, respectively, the synthesis of PAF elicited by a VEGF treatment (Fig. 9) . In contrast, pretreatment with the antisense oligonucleotide sequences complementary to Flt-1 mRNA (10 Ϫ7 M) failed to inhibit VEGF's inflammatory activity on BAEC. The scrambled oligonucleotide sequences (SCR; 10 Ϫ7 M) also failed to affect VEGF-induced PAF synthesis (Fig. 9) . Since (Fig. 1C) and a reduction of PAF synthesis by 85 and 82%, respectively, in response to VEGF (10
while the two antisense sequences complementary to Flt-1 mRNA (5 ϫ 10 Ϫ7 M) did not inhibit VEGF-induced PAF synthesis (Fig. 9) . The absence of nonspecific inhibitory effects was furthermore confirmed by pretreating BAEC with the scrambled sequences (5 ϫ 10 Ϫ7 M), which did not affect PAF synthesis. As the inhibition of Flk-1 expression had a direct effect on PAF synthesis, we performed a correlation analysis. We observed that the synthesis of PAF by BAEC treated with VEGF (10 Ϫ9 M) showed a linear correlation increment with Flk-1 protein expression: PAF synthesis % ϭ m ϫ Flk-1 expression % ϩ b, where m is the slope and b is the linearity constant. Our data showed a slope m of 0.89 and a linear constant b of 9.81 (r 2 ϭ 0.984; Fig. 10 ).
DISCUSSION
Angiogenesis is a tightly regulated process, integral to normal and pathological conditions. Crucial steps in the angiogenic process support an early increase in vascular permeability (29), closely followed by migration and proliferation of EC. Much evidence implicates VEGF and its two tyrosine kinase receptors Flt-1 and Flk-1 as major regulators of these events (16, 17, 30, 31, 37) . VEGF, unlike any other growth factors studied to date, is capable of inducing protein extravasation, and it is likely that its angiogenic properties are mediated in large part through the induction of plasma protein leakage (29) . We recently showed that VEGF's effect on vascular permeability was mediated through the synthesis of PAF by EC (11) .
In the present paper, we report that the proliferation, migration, and PAF synthesis elicited by VEGF in cultured BAEC are dose-dependent (Figs. 4, 6, and 8) , and above all, these effects were completely (proliferation) or almost completely (migration and PAF synthesis) inhibited by treating the cells with specific antisense oligonucleotide sequences complementary to Flk-1 receptor mRNA. In contrast, antisense oligonu- cleotide sequences complementary to Flt-1 receptor mRNA failed to significantly inhibit these VEGF actions.
Antisense Oligomers Specifically Inhibit Flt-1 or Flk-1 Receptor Expression-Both Flt-1 and Flk-1 are cell surface-associated receptors deemed to play a role in VEGF-induced EC activation. Recent studies have investigated their signal transduction properties using porcine aortic endothelial cells or NIH 3T3 cells transfected with a plasmid coding either for Flk-1 or Flt-1 (16, 21) . Although Flk-1-expressing cells showed a strong mitogenic and chemotactic response to VEGF treatment, no such activity was detected in cells expressing Flt-1 receptors, suggesting that Flk-1 is critical for mediating VEGF's mitogenic and chemotactic activities. However, these experiments were performed on genetically engineered cells that do not endogenously express VEGF receptors and may lack important intracellular pathways required for Flt-1 signaling. Recently, many novel VEGF-related molecules (PlGF, VEGF-C, VEGF-C-⌬N⌬C156S mutant) that vary in their potency to activate one of the two VEGF receptors preferentially were isolated and characterized (22, 23, 32) . Although the use of these analogs suggested that both receptors could mediate biological actions, they do not assess the possible formation of heterodimers, which has been proposed to occur between VEGF receptors when signaling (16) . In our study, we used antisense gene therapy to suppress specifically the Flt-1 and Flk-1 gene products. This approach allowed the use of fresh nontransfected endothelial cells that endogenously express the two VEGF receptors and the intracellular pathways found in native EC. In addition, since we were able to inhibit separately the Flt-1 and Flk-1 protein expression, our system provided also the possibility to evaluate if Flt-1 and Flk-1 heterodimerization was required to observe the VEGF biological activity.
We used two selective antisense oligonucleotide sequences for the Flt-1 receptor mRNA and two others for the Flk-1 receptor mRNA. These sequences did not contain more than three consecutive guanosines to avoid a possible interference with serum proteins including growth factors like VEGF (34) . Having the assurance that BAEC express both VEGF receptors (33), we assessed the potency of our antisense oligomers to inhibit specifically the expression and phosphorylation patterns of Flt-1 and Flk-1. As shown by Western blot analysis, BAEC expressed Flt-1 and Flk-1 proteins (Fig. 1, A-C) , which were both phosphorylated by a VEGF treatment (Fig. 3, A and  B) . Treatment of BAEC with the antisense Flt-1 oligomers (up to 5 ϫ 10 Ϫ7 M) for a 4-day period decreased the protein expression of Flt-1 receptor by as much as 94% (AS2-Flt; Fig. 1A ) and inhibited its phosphorylation by up to 50% in response to a VEGF stimulation (10 Ϫ9 M; Fig. 3A ). To a lesser extent, treatment with the antisense Flk-1 oligomers (10 Ϫ7 M) was slightly less effective at modulating Flk-1 receptor expression, with a maximum inhibition of 80% (AS1-Flk). This divergence in the inhibitory percentage is in accordance with previous reports, which showed that the biological effects of antisense oligomers are dictated in part by the kinetics of antisense target gene expression (35) . Several pieces of information suggest that basal Flk-1 expression on most type of EC is greater than that of Flt-1 (34, 47) , which might rationalize the weaker inhibitory activities of antisense Flk-1 oligomers over antisense Flt-1 oligomers at 10 Ϫ7 M. The difference between Flk-1 and Flt-1 oligomers was overcome by increasing the antisense Flk-1 oligomer concentration to 5 ϫ 10 Ϫ7 M, resulting in a greater reduction in the residual Flk-1 expression when compared with the 10 Ϫ7 M treatment, from an 80 to a 99% inhibition of Flk-1 protein expression. This latter pretreatment also prevented VEGF-induced Flk-1 protein phosphorylation by as much as 87% (Fig. 3B) . Previous reports have raised concerns that the inhibitory activities of antisense oligonucleotides probably arose from a nonspecific rather than hybridization-dependent mechanism (38, 39) . To address this issue more definitely, two groups of BAEC were pretreated with two different scrambled oligomers at similar concentrations (1-5 ϫ 10 Ϫ7 M). In contrast to the VEGF receptor antisense oligomers, the scrambled oligomers (10 Ϫ7 M) failed to modulate the normal pattern of VEGF receptors protein expression by BAEC, although it showed a slight reduction at a higher concentration (5 ϫ 10 Ϫ7 M). In addition, no cross-reactivity was observed between the Flk-1-directed antisense sequences and Flt-1 expression and vice versa (Fig. 2, A and B) . It is to be noted also that the scrambled oligomers (1-5 ϫ 10 Ϫ7 M) did not inhibit VEGF effect on EC proliferation, migration, and PAF synthesis.
Antisense Oligomer-directed Modulation of VEGF Activities-Since our antisense sequences specifically prevented both the protein expression and phosphorylation of Flt-1 or Flk-1 genes, we examined their effectiveness at modulating VEGF properties on EC. A treatment with AS1-Flk (10 Ϫ7 M) was sufficient to provide a complete inhibition of VEGF mitogenic effect (Fig. 5 ) and abolished almost completely (91% inhibition) the cellular migration induced by VEGF (Fig. 7) . However, this approach inhibited by 75% the synthesis of PAF (Fig. 9) . A higher concentration of AS1-Flk (5 ϫ 10 Ϫ7 M) not only induced a higher inhibition of Flk-1 protein expression (Fig. 1B) but also blocked the PAF synthesis elicited by VEGF by as much as 85% (Fig. 9) . Such an effect of the antisense Flk-1 oligomers directly implies Flk-1 in mediating VEGF effects on BAEC. We then evaluated if there was a correlation between the synthesis of PAF from BAEC stimulated with VEGF (10 Ϫ9 M) and the expressed Flk-1 receptors on these EC. A linear correlation was established and suggested that a complete inhibition of Flk-1 protein expression by antisense oligomers against Flk-1 mRNA would still permit VEGF to induce a 9.8% residual PAF synthesis by treated BAEC (Fig. 10) . Such a minor effect can possibly be explained either by Western blot analysis limitation to fully detect residual Flk-1 protein expression or by a partial contribution of Flt-1 stimulation. Although we observed a 99% inhibition of Flk-1 protein expression, it is possible that more than 1% of Flk-1 receptors were still present on the BAEC surface, which we could not detect either by our immunoprecipitation process or by the protein revelation by chemiluminescence after a Western blot study. The other possibility to explain the residual PAF synthesis may involve a partial effect through the activation of Flt-1 receptors. This latter hypothesis is supported by our data with PlGF treatment of BAEC.
PlGF is a secreted growth factor expressed by umbilical vein EC and placenta (42, 43) . According to its amino acid sequence, PlGF shows a partial homology to VEGF (53% homology), which might explain its ability to bind uniquely to Flt-1 (22, 32) . Therefore, PlGF can be used to study the effect of Flt-1 activation on EC. Although various concentrations of PlGF (10 Ϫ10 to 10 Ϫ8 M) failed to elicit EC proliferation and migration, PlGF at 10 Ϫ8 M induced a slight but significant increment of PAF synthesis over control levels, suggesting that Flt-1 may indeed participate in mediating PlGF and VEGF action on EC. This is in agreement with our current study and previous reports that have shown that Flt-1 stimulation either by PlGF or VEGF can induce Flt-1 phosphorylation (16, 46, 47) . However, the biological activities mediated by either VEGF or PlGF upon Flt-1 activation/phosphorylation on intracellular Ca 2ϩ elevation, cellular proliferation, migration, and procoagulant tissue factor production observed were either absent or weak (16, 32, 43, 48) as compared with Flk-1 activation/phosphorylation. Consequently, the residual PAF synthesis (10%) that we observed following an antisense Flk-1 oligomer treatment as estimated by the linear correlation may in fact be due to 1) an incomplete suppression of the Flk-1 protein expression and/or 2) intracellular signaling through Flt-1 receptor activation. In addition, VEGF may interact with Flt-1 differently than PlGF and induce a greater PAF synthesis. Therefore, these data support the hypothesis that Flt-1 stimulation is capable of mediating biological response, but to a much lower extent than Flk-1 stimulation.
VEGF, Flt-1, and Flk-1-Many studies suggest that VEGF and its two receptors may take part in the angiogenesis phenomenon. For instance, homozygous disruption of the Flk-1 gene leads to embryonic death due to failure of vasculogenesis, whereas homozygous Flt-1 disruption allows normal vascular endothelial differentiation and development but leads to a failure to assemble normal vascular channels and death (44, 45) . In our study, the inhibition of Flk-1 protein expression severely impaired VEGF effects on EC, which supports the importance of this receptor for VEGF activity.
The concept of tyrosine kinase receptor heterodimerization has been demonstrated previously for the platelet-derived growth factor receptor-␣ and -␤, which form hetero-and homodimers, depending on the stimulating platelet-derived growth factor isoform (40, 41) . In this report, the fact that our antisense Flt-1 oligomers blocked Flt-1 protein expression but failed to modulate VEGF effects on EC does not support the hypothesis that activated Flk-1 receptors need to heterodimerize with Flt-1 receptors to induce its biological activities.
In summary, we have demonstrated that antisense oligomerdirected inhibition of Flk-1 receptor expression severely impaired VEGF-induced EC proliferation, migration, and PAF synthesis. In contrast, inhibition of Flt-1 protein expression did not significantly affect VEGF activity, suggesting that activation of Flk-1 is sufficient to mediate VEGF effects on EC and that VEGF receptor heterodimerization is not essential for Flk-1 signaling. These results were furthermore supported by the use of a Flt-1-specific agonist (PlGF), which induced only a slight increase in PAF synthesis. Future studies are aimed at blocking VEGF angiogenic effect in vivo with the antisense oligomers described in this paper.
